Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
$1.70
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.70
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.05 - $8.00
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$51.43M
Enterprise Value-$56.47M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 26, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding31,555,126
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)11.51
Price to Sales (P/S)0.00
P/FCF Ratio-29.72
Enterprise Value/Market Cap-1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.52
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$10.50Price Target Upside517.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-agnostic EnrollmentAnalyst notes that enrolling a serous cohort without requiring pre-treatment biopsies could broaden patient access and support wider commercial adoption compared with a biomarker-selected approach that requires biopsies.
Efficacy In Serous SubtypeAnalyst highlights that ACR-368 achieved notably higher response rates in serous endometrial cancer versus other subtypes, suggesting stronger efficacy in that patient group.
Pipeline Early ActivityAnalyst notes that ACR-2316 has shown enhanced antitumor activity in preclinical studies and early tumor shrinkage signals in initial trials, indicating potential upside across the pipeline.
Bears Say
Funding PressureAnalyst flags that cash resources may be modest relative to development spending, creating potential funding pressure for ongoing trials.
Regulatory Pathway UncertaintyAnalyst notes that pursuing multiple development strategies and proposed trial designs leaves the regulatory approval pathway unclear, increasing execution risk for a registrational program.
Retrospective Evidence RiskAnalyst cautions that the encouraging efficacy findings stem from retrospective subgroup analysis and must be confirmed in a prospective setting, so initial signals may not translate to registrational success.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $8.00 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $51.43M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 71 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.591 by $0.121.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,555,126 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.591. Following the earnings report the stock price went up 8.213%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (517.65% Upside)
$10.50 (517.65% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.2%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
-32.32%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$10.50
▲(517.65% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
44.25% Insiders
2.21% Mutual Funds
34.78% Other Institutional Investors
16.92% Public Companies and Individual Investors
Options Prices
Currently, No data available
---